IceCure Medical (NASDAQ:ICCM) Trading Down 0.7%

IceCure Medical Ltd (NASDAQ:ICCM) traded down 0.7% on Monday . The stock traded as low as $0.72 and last traded at $0.74. 717,074 shares were traded during mid-day trading, an increase of 45% from the average session volume of 493,939 shares. The stock had previously closed at $0.74.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Alliance Global Partners raised their target price on shares of IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research note on Wednesday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of IceCure Medical in a research note on Wednesday, June 5th.

IceCure Medical Stock Down 0.7 %

The firm has a 50 day simple moving average of $0.98 and a two-hundred day simple moving average of $1.16. The stock has a market capitalization of $33.53 million, a P/E ratio of -2.23 and a beta of 0.57. The company has a quick ratio of 2.88, a current ratio of 3.39 and a debt-to-equity ratio of 0.03.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.80 million. IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. During the same quarter in the prior year, the business earned ($0.08) earnings per share. On average, equities research analysts expect that IceCure Medical Ltd will post -0.28 earnings per share for the current year.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.